# REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

> **NCT03435640** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nektar Therapeutics** · enrollment: 64 (actual)

## Conditions studied

- Melanoma
- Merkel Cell Carcinoma
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Colorectal Cancer
- Sarcoma

## Interventions

- **DRUG:** NKTR-262
- **DRUG:** bempegaldesleukin
- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT03435640
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-15
- **Primary completion:** 2022-05-09
- **Final completion:** 2022-05-09
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03435640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03435640, "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03435640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*